GeoPolitics Pulse

The Heartbeat of World events

Dupixent® (dupilumab) Approved in the European Union as the – GlobeNewswire

by ·

(NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) to treat eosinophilic esophagitis (EoE) …Read More

Related posts:

  1. Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy …
  2. Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
  3. Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
  4. Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for …
  5. Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in …